Literature DB >> 410885

The SC5b-7 complex: formation, isolation, properties, and subunit composition.

E R Podack, W P Kolb, H J Müller-Eberhard.   

Abstract

Activation of C in C8-depleted serum results in the formation of a soluble complex containing C5, C6, and C7. The complex has an electrophoretic mobility of an alpha-globulin, an s-rate of 18.5S, and a m.w. of 668,000 daltons. This complex was isolated and upon SDS polyacrylamide gel electrophoresis it was found to contain, in addition to C5b, C6 and C7, an 88,000 dalton glycoprotein. The protein was identified as the band V protein of the soluble C5b-9 complex. It is referred to as SIIIs-protein, or S-protein. Since the S-protein does not bind to C5b-6, it is concluded that it is incorporated during the fusion of C5b-6 with C7. The SC5b-7 complex exhibits the same neoantigen as the SC5b-9 complex, but compared to the C5b-6 complex it appears to contain an additionally qualitatively distinct neoantigen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 410885

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Proteolytic transformation of SC5b-9 into an amphiphilic macromolecule resembling the C5b-9 membrane attack complex of complement.

Authors:  S Bhakdi; B Bhakdi-Lehnen; J Tranum-Jensen
Journal:  Immunology       Date:  1979-08       Impact factor: 7.397

2.  Survival signals of hepatic stellate cells in liver regeneration are regulated by glycosylation changes in rat vitronectin, especially decreased sialylation.

Authors:  Kotone Sano; Yasunori Miyamoto; Nana Kawasaki; Noritaka Hashii; Satsuki Itoh; Misaki Murase; Kimie Date; Miki Yokoyama; Chihiro Sato; Ken Kitajima; Haruko Ogawa
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

3.  Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase A.

Authors:  D Chain; B Korc-Grodzicki; T Kreizman; S Shaltiel
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

Review 4.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli.

Authors:  G S Chhatwal; K T Preissner; G Müller-Berghaus; H Blobel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation.

Authors:  Anna M Blom; Simone Bergmann; Marcus Fulde; Kristian Riesbeck; Vaibhav Agarwal
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

7.  Ail provides multiple mechanisms of serum resistance to Yersinia pestis.

Authors:  Joshua J Thomson; Sarah C Plecha; Eric S Krukonis
Journal:  Mol Microbiol       Date:  2018-10-26       Impact factor: 3.501

8.  Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.

Authors:  L Milis; C A Morris; M C Sheehan; J A Charlesworth; B A Pussell
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

9.  Complement inhibition by human vitronectin involves non-heparin binding domains.

Authors:  M Sheehan; C A Morris; B A Pussell; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Physicochemical characterization of human S-protein and its function in the blood coagulation system.

Authors:  K T Preissner; R Wassmuth; G Müller-Berghaus
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.